CoChat
Sign Up
Cited by 128Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTreatment of Major DepressionPsychological Treatments and Disorders

The DOI matches its Crossref record; 139 of the 140 references it cites were found in a registry or an index.

Current Considerations in the Treatment of Generalized Anxiety Disorder

Katzman, Martin A.·2009·CNS Drugs
DOI 10.2165/00023210-200923020-00002
Open this paper in CoChat — free account

Abstract

Generalized anxiety disorder (GAD) is a chronic disorder that frequently co-occurs with a variety of co-morbidities in patients with somatic conditions and other mental disorders. GAD is highly prevalent and is one of the most common anxiety disorders seen by primary care physicians. The individual and societal cost associated with GAD is high and the marked level of impairment experienced by patients with this disorder is equivalent in magnitude to that reported in patients with major depressive disorder. Furthermore, patients with GAD are at risk of suicide or suicide attempts, and are frequent users of healthcare services. Thus, GAD is a serious and chronic condition that requires appropriate long-term treatment. The focus of acute treatment for patients with GAD is the improvement of symptoms, while the primary goal of long-term clinical management is remission, i.e. the complete resolution of both symptoms and functional impairment. The consensus across current treatment guidelines is that first-line treatment for patients with GAD should consist of an antidepressant, either a selective serotonin reuptake inhibitor (SSRI) such as sertraline, paroxetine or escitalopram, or a selective serotonin noradrenaline (norepinephrine) reuptake inhibitor (SNRI) such as venlafaxine or duloxetine. However, the SSRIs and SNRIs have efficacy limitations, such as lack of response in many patients, a 2- to 4-week delay before the onset of symptom relief, lack of full remission, and risk of relapse. In addition, there are troublesome adverse effects associated with both the SSRIs and SNRIs. Evidence from early clinical studies of the atypical antipsychotics in the treatment of anxiety and GAD indicate that they may have a potential role in the treatment of GAD, either as monotherapy or as augmentation to standard treatment.

Overview

Integrity signals

Registry

Crossref · 10.2165/00023210-200923020-00002

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 24

  1. Keller, 2002, J Clin Psychiatry, 63, 11
  2. Culpepper, 2002, J Clin Psychiatry, 63, 35
  3. Stein, 2001, J Clin Psychiatry, 62, 29
  4. Wittchen, 2002, J Clin Psychiatry, 63, 24
  5. Smit, 2006, J Ment Health Policy Econ, 9, 193
  6. 1992, Vol. 3
  7. 2005, Vol. 3, 2nd rev
  8. Ballenger, 2001, J Clin Psychiatry, 62, 11
  9. Gorman, 2002, Psychopharmacol Bull, 36, 49
  10. Lenox-Smith, 2003, Br J Gen Pract, 53, 772
  11. Chessick, 2006, Cochrane Database Syst Rev, &NA;, CD006115
  12. Pollack, 1997, J Clin Psychiatry, 58, 19
  13. Roerig, 1999, J Am Pharm Assoc, 39, 811
  14. Pollack, 2001, J Clin Psychiatry, 62, 20, 10.4088/JCP.v62n0508 · DOI
  15. Lang, 2004, J Clin Psychiatry, 65, 14
  16. Hunot, 2007, Cochrane Database Syst Rev, &NA;, CD001848
  17. Borkovec, 2001, J Clin Psychiatry, 62, 37
  18. Chambless, 1993, J Consult Clin Psychol, 61, 248, 10.1037/0022-006X.61.2.248 · DOI
  19. Mohlman, 2003, Am J Geriatr Psychiatry, 11, 24
  20. Hedlund, 1979, J Oper Psychiatry, 10, 149
  21. Endicott, 1993, Psychopharmacol Bull, 29, 321
  22. Thase, 2006, Int J Neuropsychopharmacol, 9, S237
  23. Carson, 2004, Psychopharmacol Bull, 38, 38
  24. Ballenger, 2001, J Clin Psychiatry, 62, 5

Cited by

Sorted by citations

See all 128

Related

See all

Metadata

Authors
Katzman, M. A.
Affiliations
START Clinic (CA)
Corresponding author
Katzman, Martin A.
ORCID
Katzman, Martin A.
Venue
CNS Drugs
Publisher
Springer Science and Business Media LLC
Published
2009
Volume
23
Issue
2
Pages
103-120
ISSN
1172-7047 (ISSN-L)
DOI
10.2165/00023210-200923020-00002
OpenAlex
W2067903360
Cited by
128
References
140
Citations by year
2026: 4 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 10 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 4 · 2017: 4 · 2016: 7 · 2015: 9 · 2014: 12 · 2013: 11 · 2012: 16
FWCI
2.15
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • AstraZeneca
  • H. Lundbeck A/S
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
Keywords
generalized anxiety disorder, antidepressants, selective serotonin reuptake inhibitors, atypical antipsychotics, augmentation therapy, remission, relapse, adverse drug reactions, comorbidities, primary care, treatment guidelines
MeSH terms
Anxiety Disorders, Clinical Trials as Topic, Drug Resistance, Humans, Psychotherapy, Antipsychotic Agents, Selective Serotonin Reuptake Inhibitors, Practice Guidelines as Topic, Adrenergic Uptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review